课题基金 / 基金详情

Small molecule analogues (SMAs) of an immunomodulatory helminth product provide a novel approach to dissecting macrophage signal transduction pathways

Small molecule analogues (SMAs) of an immunomodulatory helminth product provide a novel approach to dissecting macrophage signal transduction pathways
免疫调节蠕虫产品的小分子类似物 (SMA) 提供了一种剖析巨噬细胞信号转导途径的新方法
批准号:
BB/E013929/1
负责人:
William Harnett
金额:
$99.47万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2007
资助国家:
英国
项目状态:
已结题
起止时间:
2007 至 --

项目摘要

项目成果

William Harnett的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The basic unit of life is the cell and all living organisms on Earth are made up of one or more of these. In order to survive and function a cell must be able to communicate with its environment and respond to the signals that it receives. Within the human body, cells respond to signals that they receive either when they make contact with other cells or when they interact with molecules such as proteins and hormones, present in fluid components of the body such as blood. These interactions can trigger changes in cells that may ultimately translate into altered functional capability. This is because the interactions activate biochemical pathways ('signal tranduction pathways') in cells and these pathways promote changes in the cell's molecular composition. For example, the cell may start to produce a new protein that bestows on it properties, previously unpossessed. The response of a cell to a signal is dependent on the nature and quantity of the signal and the signal transduction network of the cell responds to and deciphers each signal to produce an appropriate response. Although it is possible for a cell to produce thousands of new proteins, the signal transduction network uses a resticted number of components to facilitate this. Thus the key to understanding how the cell responds to signals is to elucidate which members of the signal transduction pathway are activated in any particular case. The macrophage is a cell that is involved in fighting disease. As a consequence of this, not only does it have to respond to the types of signal referred to above, it responds to signals it receives from infectious agents attempting to invade the body. The signals come in the form of molecules of the pathogens that bind to receptors on the surface of the macrophage. A good example of a type of receptor is the Toll-like family of receptors. These respond to pathogen products by activating signal transduction pathways that ultimately result in the production within the macrophage of a group of molecules called pro-inflammatory cytokines. These molecules are secreted and have an important role in combatting infectious agents. However, their production must be carefully regulated as left unchecked they have the potential to cause more harm than good, as overproduction of these molecules is associated with many chronic inflammatory diseases. The key question that we wish to address is how the macrophage signal transduction network regulates production of individual inflammatory mediators. We have found that a worm pathogen product that we discovered (ES-62) inhibits certain signal transduction pathways in macrophages and certain other cells of the immune system. We have investigated a number of small molecule analogues (SMAs) of ES-62 and found that although some of them possess inhibitory activity, this is often more focussed than that associated with the parent molecule and also differs in target amongst SMAs. Thus it appears to be possible to inhibit production of a particular cytokine and this offers the opportunity to then establish the signalling events underlying regulation of this cytokine. The aim of this project is thus to make a larger number (a 'library') of related SMAs and to test their ability to inhibit pro-inflammatory cytokine responses and thus understand their associated regulation. If successful we will provide novel and important information on how macrophages respond to pathogens. Furthermore, as signalling pathways are highly conserved in evolution, we will advance knowledge at the fundamental level in the fields of cell biology and biochemistry as a whole.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1177/0961203315591031
发表时间: 2015-11
期刊: Lupus
影响因子: 2.6
作者: [Rodgers DT, Pineda MA, Suckling CJ, Harnett W, Harnett MM]
通讯作者: Harnett MM
DOI: 10.1021/jm401251p
发表时间: 2013-12-27
期刊: Journal of medicinal chemistry
影响因子: 7.3
作者: [Al-Riyami L, Pineda MA, Rzepecka J, Huggan JK, Khalaf AI, Suckling CJ, Scott FJ, Rodgers DT, Harnett MM, Harnett W]
通讯作者: Harnett W
DOI: 10.3390/molecules23102669
发表时间: 2018-10-17
期刊: Molecules (Basel, Switzerland)
影响因子: --
作者: [Doonan J, Thomas D, Wong MH, Ramage HJ, Al-Riyami L, Lumb FE, Bell KS, Fairlie-Clarke KJ, Suckling CJ, Michelsen KS, Jiang HR, Cooke A, Harnett MM, Harnett W]
通讯作者: Harnett W
DOI: 10.1016/j.ijpara.2014.05.001
发表时间: 2014-08
期刊: INTERNATIONAL JOURNAL FOR PARASITOLOGY
影响因子: 4
作者: [Rzepecka, Justyna, Coates, Michelle L., Saggar, Moninder, Al-Riyami, Lamyaa, Coltherd, Jennifer, Tay, Hwee Kee, Huggan, Judith K., Janicova, Lucia, Khalaf, Abedawn I., Siebeke, Ivonne, Suckling, Colin J., Harnett, Margaret M., Harnett, William]
通讯作者: Harnett, William
How does the immunomodulatory parasitic worm product ES-62 rewire bone marrow cells to increase healthspan and lifespan in obesity-accelerated ageing?
  • 批准号:
    MR/V000683/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $89.06万
  • 财政年份:
    2021
  • 负责人:
    William Harnett
  • 依托单位:
Does the parasitic worm product ES-62 resolve aberrant chronic inflammation by sensing and normalising the gut microbiome and intestinal integrity?
  • 批准号:
    BB/V000993/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $9.33万
  • 财政年份:
    2021
  • 负责人:
    William Harnett
  • 依托单位:
Can studying the mechanism of action of the parasitic worm-derived immunomodulator ES-62, inform on how to slow ageing and improve healthspan?
  • 批准号:
    BB/M029662/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $39.2万
  • 财政年份:
    2016
  • 负责人:
    William Harnett
  • 依托单位:
国内基金
海外基金
新型小分子蛋白—人肝细胞生长因子三环域(hHGFK1)抑制破骨细胞及治疗小鼠骨质疏松的疗效评估与机制研究
  • 批准号:
    82370885
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    姚晨
  • 依托单位:
活细胞单分子成像定量研究EGFR内吞途径命运选择
中性粒细胞在体内条件下重编程为造血干祖细胞的研究
  • 批准号:
    92068101
  • 项目类别:
    重大研究计划
  • 资助金额:
    80.0万元
  • 批准年份:
    2020
  • 负责人:
    程林
  • 依托单位:
小分子化合物促进肝细胞增殖和肝脏再生的研究
  • 批准号:
    32000504
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    郭任
  • 依托单位: